Upgrade to SI Premium - Free Trial

Form 3 BELITE BIO, INC For: Mar 18 Filed by: Lin Yu-Hsin

March 18, 2026 2:24 PM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Lin Yu-Hsin
(Last) (First) (Middle)
12750 HIGH BLUFF DRIVE, SUITE 475
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026 		3. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
American depositary share (1) 180,134
D
Ordinary Share 172,949
D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (2) 12/22/2030 Ordinary Shares 206,954 0.4386 D
Stock Option (right to buy) (3) 04/17/2032 Ordinary Shares 27,778 6 D
Stock Option (right to buy) (4) 07/16/2033 Ordinary Shares 166,667 14.45 D
Stock Option (right to buy) (5) 08/28/2034 Ordinary Shares 208,334 48.46 D
Stock Option (right to buy) (6) 02/11/2035 Ordinary Shares 200,000 54.88 D
Stock Option (right to buy) (7) 10/06/2035 Ordinary Shares 40,000 77.4 D
Stock Option (right to buy) (8) 10/27/2035 Ordinary Shares 80,000 93.02 D
Stock Option (right to buy) (9) 01/08/2036 Ordinary Shares 150,000 158.36 D
Explanation of Responses:
1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer.
2. The option to purchase 206,954 ordinary shares had vested prior to March 18, 2026.
3. The option to purchase 27,778 ordinary shares had vested prior to March 18, 2026.
4. The option to purchase 145,833 ordinary shares had vested prior to March 18, 2026. The option shall vest as to the remaining 20,834 ordinary shares in five equal and continuous monthly installments at the end of each month from March 2026 to July 2026, subject to continued service to the Issuer on each such date.
5. The option to purchase 83,334 ordinary shares had vested prior to March 18, 2026. The option shall vest as to the remaining 125,000 ordinary shares in 18 monthly equal and continuous installments at the end of each month from March 2026 to August 2028, subject to continued service to the Issuer on each such date.
6. The option shall vest as to 200,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following February 12, 2025, subject to continued service to the Issuer on each such date.
7. The option to purchase 40,000 ordinary shares had vested prior to March 18, 2026.
8. The option to purchase 80,000 ordinary shares had vested prior to March 18, 2026.
9. The option shall vest (i) as to 50,000 ordinary shares on January 9, 2027, (ii) as to 50,000 ordinary shares on January 9, 2028, and (iii) as to 50,000 ordinary shares on January 9, 2029.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Yu-Hsin Lin 03/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ATTACHMENTS / EXHIBITS

EX-24

Categories

SEC Filings